Universidad Peruana Cayetano Heredia
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Beck, Hans-Peter | |
| dc.contributor.author | Wampfler, Rahel | |
| dc.contributor.author | Carter, Nick | |
| dc.contributor.author | Koh, Gavin | |
| dc.contributor.author | Osorio, Lyda | |
| dc.contributor.author | Rueangweerayut, Ronnatrai | |
| dc.contributor.author | Krudsood, Srivcha | |
| dc.contributor.author | Lacerda, Marcus V. | |
| dc.contributor.author | Llanos Cuentas, Elmer Alejandro | |
| dc.contributor.author | Duparc, Stephan | |
| dc.contributor.author | Rubio, Justin P. | |
| dc.contributor.author | Green, Justin A. | |
| dc.date.accessioned | 2019-02-06T14:57:40Z | |
| dc.date.available | 2019-02-06T14:57:40Z | |
| dc.date.issued | 2015 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/5487 | |
| dc.description.abstract | UNLABELLED: Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse. | en_US |
| dc.language.iso | eng | |
| dc.publisher | Oxford University Press | |
| dc.relation.ispartofseries | Journal of Infectious Diseases | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | Humans | en_US |
| dc.subject | Genotype | en_US |
| dc.subject | Plasmodium vivax | en_US |
| dc.subject | Double-Blind Method | en_US |
| dc.subject | efficacy | en_US |
| dc.subject | Dose-Response Relationship, Drug | en_US |
| dc.subject | Plasmodium vivax/genetics | en_US |
| dc.subject | Secondary Prevention | en_US |
| dc.subject | Aminoquinolines/administration & dosage/therapeutic use | en_US |
| dc.subject | antihypnozoite | en_US |
| dc.subject | Antimalarials/administration & dosage/therapeutic use | en_US |
| dc.subject | Chloroquine/administration & dosage/therapeutic use | en_US |
| dc.subject | genotyping | en_US |
| dc.subject | Malaria, Vivax/drug therapy | en_US |
| dc.subject | Primaquine/administration & dosage/therapeutic use | en_US |
| dc.subject | tafenoquine | en_US |
| dc.title | Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.1093/infdis/jiv508 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.08 | |
| dc.relation.issn | 1537-6613 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
